sur Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics Financial Update and Clinical Milestones
Protagonist Therapeutics, a biopharmaceutical company, announced its third-quarter 2024 financial results and provided insights into upcoming clinical trial milestones. The company expects top-line results for its JNJ-2113 Phase 3 psoriasis trials by Q4 2024 and for the Phase 2b ulcerative colitis study by Q1 2025. Additionally, results for the rusfertide Phase 3 trial in polycythemia vera are anticipated in Q1 2025.
The company reported cash reserves of $583.3 million as of September 30, 2024, estimating sufficient financial resources through 2027. JNJ-2113, a Phase 3 oral IL-23 receptor antagonist, is under development for psoriasis and ulcerative colitis. Discovery programs include developing an oral IL-17 peptide antagonist, with a candidate nomination expected by Q4 2024.
Financially, Protagonist revealed a net loss of $33.2 million for Q3 2024. Despite increased research and administrative expenses, the company reported a net income of $143.5 million for the first nine months of 2024, influenced by revenue from its Takeda collaboration.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Protagonist Therapeutics, Inc.